171
Views
0
CrossRef citations to date
0
Altmetric
Systematic Review

ADME Pharmacogenetics: Future Outlook for Russia

, ORCID Icon, &
Pages 847-865 | Received 07 Feb 2019, Accepted 01 Apr 2019, Published online: 01 Aug 2019
 

Abstract

This systematic review reflects the results of pharmacogenetic studies in the Russian Federation aimed at studying the genes involved in the drug biotransformation system. The works of Russian researchers found by us are mostly devoted to microsomal liver oxidation enzymes (metabolism) and membrane transporter systems (absorption and excretion). This review presents population-ethnic and associative clinical studies on the genes of the CYP450 system, noncytochrome oxidation enzymes (SULT1A1, CES1), membrane transporter system genes (ABCB1, SLCO1B1) and warfarin biotransformation enzymes (VKORC1, GGCX). The information is structured in the form of 11 tables, divided by regions of the Russian Federation.

Supplementary data

To view the supplementary data that accompany this paper please visit the journal website at:

https://www.futuremedicine.com/doi/suppl/10.2217/pgs-2019-0013

Financial & competing interests disclosure

This study was supported by the Russian Science Foundation (Grant No. 18-75-00112) ‘Genetic determinants of drug sensitivity to the rooted peoples of the North Caucasus, the Republic of Crimea, the Volga region and Siberia’. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Additional information

Funding

This study was supported by the Russian Science Foundation (Grant No. 18-75-00112) ‘Genetic determinants of drug sensitivity to the rooted peoples of the North Caucasus, the Republic of Crimea, the Volga region and Siberia’. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed. No writing assistance was utilized in the production of this manuscript.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.